Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-01-11
2011-01-11
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S357000, C544S229000, C514S063000
Reexamination Certificate
active
07868005
ABSTRACT:
The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1:and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.
REFERENCES:
patent: 6124319 (2000-09-01), MacCoss et al.
patent: 6525070 (2003-02-01), Rigby et al.
patent: 7417045 (2008-08-01), Anilkumar et al.
patent: 7566718 (2009-07-01), Wong et al.
patent: 2002/0018776 (2002-02-01), Hancock
patent: 2003/0055054 (2003-03-01), Medina et al.
patent: 2006/0276448 (2006-12-01), Zeng et al.
patent: 2006/0276457 (2006-12-01), Yu et al.
patent: 2006/0276479 (2006-12-01), Kim et al.
patent: 2007/0021611 (2007-01-01), McGuinness et al.
patent: 2007/0082913 (2007-04-01), Kim et al.
patent: 2008/0039474 (2008-02-01), Rosenblum et al.
patent: 2008/0058343 (2008-03-01), Rosenblum et al.
patent: 2008/0292589 (2008-11-01), Anilkumar et al.
patent: WO93/10091 (1993-05-01), None
patent: WO93/14077 (1993-07-01), None
patent: WO99/20606 (1999-04-01), None
patent: WO00/066558 (2000-11-01), None
patent: WO02/085861 (2002-10-01), None
patent: WO03/070242 (2003-08-01), None
patent: WO03/082335 (2003-10-01), None
patent: WO03/098185 (2003-11-01), None
patent: WO03/101970 (2003-12-01), None
patent: WO2006/088921 (2006-08-01), None
Vippagunta et al, “Crystalline Solids” Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Gavezzotti, “Are Crystal Structures Predictable?” Accounts of Chemical Research, vol. 27, pp. 309-314 (1994).
Lazzeri and Romagnani, “CXCR3-binding Chemokines: Novel Multifunctional Therapeutic Targets” Current Drug Targets—Immune, Endocrine & Metabololic Disorders, vol. 5, pp. 109-118 (2005).
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
Angiolilo, Anne L., et al.; “Human Interferon-inducible Protein 10 is a Potent Inhibitor of Angiogenesis In Vivo”; The Journal of Experimental Medicine; 182:155-162 (1995).
Baggiolini, Marco, et al.; “Interleukin-8 and Related Chemotactic Cytokines—CXC and CC Chemokines”; Advances in Immunol.; 55:97-179 (1994).
Baggiolini, Marco, et al.; “CC chemokines in allergic inflammation”; Immunology Today; 15(3):127-133 (1994).
Clark-Lewis, Ian, et al.; “Structure-Activity Relationships of Interleukin-8 Determined Using Chemically Synthesized Analogs”; The Journal of Biological Chemistry; 266(34):23128-23134 (1991).
Clark-Lewis, Ian, et al.; “Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg”; Proc. Natl. Acad. Sci. USA; 90:3574-3577 (1993).
Cole, Katherine E., et al.; “Interferon-inducible T Cell Alpha Chemoattractant (I-TAC): A Novel Non-ELR CXC Chemokine with Potent Activity on Activated T Cells through Selective High Affinity Binding to CXCR3”; J. Exp. Med.; 187(12):2009-2021 (1998).
Farber, Joshua M.; “A macrophage mRNA selectively induced by γ—interferon encodes a member of the platelet factor 4 family of cytokines”; Proc. Natl. Acad. Sci. USA; 87:5238-5242 (1990).
Farber, Joshua M.; “HuMIG: A New Human Member of the Chemokine Family of Cytokines”; Biochemical and Biophysical Research Communications; 192(1):223-230 (1993).
Galy, Anne H. M., et al.; “IL-1, IL-4, and IFN-γ Differentially Regulate Cytokine Production and Cell Surface Molecule Expression in Cultured Human Thymic Epithelial Cells”; The Journal of Immunology; 147(11):3823-3830 (1991).
Hebert, Caroline A., et al.; “Scanning Mutagenesis of Interleukin-8 Identifies a Cluster of Residues Required for Receptor Binding”; The Journal of Biological Chemistry; 266(28):18989-18994 (1991).
Liao, Fang, et al.; “Human Mig Chemokine: Biochemical and Functional Characterization”; J. Exp. Med.; 182:1301-1314 (1995).
Loetscher, Marcel, et al.; “Chemokine Receptor Specific for IP10 and Mig: Structure, Function, and Expression in Activated T-Lymphocytes”; J. Exp. Med.; 184:963-969 (1996).
Loetscher, Pius, et al.; “Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes”; FASEB J.; 8:1055-1060 (1994).
Luster, Andrew D., et al.; “Ip-10, a -C-X-C- Chemokine, Elicits a Potent Thymus-dependent Antitumor Response In Vivo”; J. Exp. Med.; 178:1057-1065 (1993).
Luster, Andrew D., et al.; “The IP-10 Chemokine Binds to a Specific Cell Surface Heparan Sulfate Site Shared with Platelet Factor 4 and Inhibits Endothelial Cell Proliferation”; J. Exp. Med.; 182:219-231 (1995).
Luster, Andrew D., et al.; “γ-Interferon transcriptionally regulates an early-response gene containing homology to platelet proteins”; Nature; 315:672-676 (1985).
Qin, Shixin, et al.; “The Chemokine Receptors CXCR3 and CCR5 Mark Subsets of T Cells Associated with Certain Inflammatory Reactions”; J. Clin. Invest.; 101(4):746-754 (1998).
Schall, Thomas J., et al.; “Hemokines, leukocyte trafficking, and inflammation”; Current Opinion in Immunology; 6:865-873 (1994).
Seitz, Michael, et al.;. “Enhanced Productionof Neutrophil-activiating Peptide-1/Interleukin-8 in Rheumatoid Arthritis”; Journal Clin. Invest.; 87:463-469 (1991).
Springer, Timothy A.; “Traffic Signals on Endothelium for Lymphocyte Recirculation and Leukocyte Emigration”; Annu. Rev. Physio.; 57:827-872 (1995).
Taub, Dennis D., et al.; “Recombinant Human Interferon-inducible Protein 10 is a Chemoattractant for Human Monocytes and T Lymphocytes and Promotes T Cell Adhesion to Endothelial Cells”; The Journal of Experimental Medicine; 177:1809-1814 (1993).
Taub, Dennis D., et al.; “α and β Chemokines Induce NK Cell Migration and Enhance NK-Mediated Cytolysis”; The Journal of Immunol.; 155:3877-3888 (1995).
Uguccioni, Mariagrazia, et al.; “Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1α and MIP-1β on human monocytes”; Eur. J. Immunol.; 25:64-68 (1995).
Qingbei Zeng et al., U.S. Appl. No. 12/519,970; Preliminary Amendment—Filed Jun. 18, 2009.
International Search Report for International Application No. PCT/US2006/005267 dated Jul. 18, 2006.
Notice of Allowance in U.S. Appl. No. 11/545,201 mailed Nov. 17, 2009.
Notice of Allowance in U.S. Appl. No. 11/353,697 mailed Jan. 7, 2010.
Notice of Allowance in U.S. Appl. No. 11/688,014 mailed Jan. 19, 2010.
Anilkumar Gopinadhan N.
Baldwin John J.
Dong Guizhen
Hobbs Douglas W.
Jiang Yueheng
Banerjee Krishna G.
Kalyanaraman Palaiyur
Meade Eric A.
Schering Corporation
Wilson James O
LandOfFree
Pyrazinyl substituted piperazine-piperidines with CXCR3... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazinyl substituted piperazine-piperidines with CXCR3..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazinyl substituted piperazine-piperidines with CXCR3... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2712787